Article

A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Intracisternal Engineered Autologous Exosomes (NV-101) to Restore Neuronal Proteostasis in Early Alzheimer’s Disease: The RESTORE Protocol

2025-09-09

Abstract excerpt

<h4>Background</h4> The current therapeutic landscape for Alzheimer’s disease (AD) offers limited efficacy. The failure of the neuronal proteostasis network a system critical for preventing toxic protein aggregation is a fundamental pathological process in AD. Molecular chaperones, which are deficient in the AD brain, represent a compelling therapeutic target. A major obstacle has been delivering large biologics...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bc717315-af18-5b1e-88eb-3a1ccafd4558
DOI: 10.1101/2025.09.04.25335118

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Intracisternal Engineered Autologous Exosomes (NV-101) to Restore Neuronal Proteostasis in Early Alzheimer’s Disease: The RESTORE ProtocolDOI 10.1101/2025.09.04.25335118Read

Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s DiseaseSemantic proximity Read

Porcine plasma-derived extracellular vesicles orchestrate multi- target neuroimmune reconfiguration to alleviate Alzheimer's diseaseSemantic proximity Read

Nanobody Therapeutics in Alzheimer’s Disease: From Molecular Mechanisms to Translational ApproachesSemantic proximity Read

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept TrialSemantic proximity Read

mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's diseaseSemantic proximity Read

Mesenchymal Stem Cell-Derived Exosomes as a Neuroregeneration Treatment for Alzheimer's DiseaseSemantic proximity Read

Therapeutic Potential of Arimoclomol Nanomicelles: In Vitro Impact on Alzheimer’s and Parkinson’s Pathology and Correlation with In Vivo Inflammatory ResponseSemantic proximity Read

Intranasally Administered EVs from hiPSC-derived NSCs Alter the Transcriptomic Profile of Activated Microglia and Conserve Brain Function in an Alzheimer’s ModelSemantic proximity Read

Extracellular Vesicles for Alzheimer’s Disease and Dementia DiagnosisSemantic proximity Read

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialSemantic proximity Read

Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer’s Disease patients and cognitively normal individualsSemantic proximity Read

Application of Multiomics Approach to Investigate the Therapeutic Potentials of Stem Cell-derived Extracellular Vesicle Subpopulations for Alzheimer’s DiseaseSemantic proximity Read